NSE devices may not be subject to recall
This article was originally published in The Gray Sheet
Executive Summary
FDA will evaluate the need for reprocessors to recall distributed devices deemed "not substantially equivalent" on a case-by-case basis, according to a CDRH release. AdvaMed is concerned that the agency's language does not obligate reprocessors to notify end users that NSE devices are no longer legally allowed to be marketed. The trade group is requesting FDA to reconsider its position on contacting end users directly...
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.